Patents Represented by Attorney, Agent or Law Firm Bertram I. Rowland
  • Direct measuring assay strip and method of use thereof
    Patent number: 4999287
    Abstract: Methods and compositions are provided for measuring an analyte without instrumentation. The device employs a stripstick which may include as its components, a discontinuous flow path, which is made continuous after transfer of the sample, means for automatically metering the volume of a sample, and means for providing a sharply delineated color front. The method finds particular use where a limited amount of substrate is provided for an enzyme on a sample pad.
    Type: Grant
    Filed: May 19, 1988
    Date of Patent: March 12, 1991
    Assignee: Chemtrak Corporation
    Inventors: Michael P. Allen, Robert B. Shibuya
  • Biodegradable ocular implants
    Patent number: 4997652
    Abstract: Encapsulated drugs are employed for introduction into the chambers of the eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
    Type: Grant
    Filed: May 31, 1989
    Date of Patent: March 5, 1991
    Assignee: Visionex
    Inventor: Vernon G. Wong
  • Phosphatidyl treatment of viral disease
    Patent number: 4997761
    Abstract: Phosphatides are shown to have antiviral activity, where the phosphatides are characterized by having a polyunsaturated fatty acid at the sn2 position. By contacting cells susceptible to or infected with a virus, particularly a retrovirus, the proliferation of the virus is substantially inhibited.
    Type: Grant
    Filed: October 6, 1987
    Date of Patent: March 5, 1991
    Assignee: Houston Biotechnology Incorporated
    Inventor: Marti Jett-Tilton
  • Microassay for detection of DNA and RNA
    Patent number: 4996144
    Abstract: A novel hybridization diagnostic technique is involved employing micromanipulation of cells for detection of DNA or RNA in the cells. Cellular suspensions are employed, the DNA or RNA purified by microextraction using liquid media having differential solubilization properties, whereby the nucleic acid is retained in an aqueous microdrop. The nucleic acid in the microdrop may then be assayed with a nucleic acid probe in accordance with conventional ways.
    Type: Grant
    Filed: January 25, 1985
    Date of Patent: February 26, 1991
    Assignee: Calgene, Inc.
    Inventors: Anne Crossway, Catherine M. Houck
  • T-cell activation related gene
    Patent number: 4994369
    Abstract: Nucleic acids and peptides are provided which can be used for detecting the status of functional T-lymphocytes as to stimulation and the time of stimulation. The nucleic acids and peptides may be provided by cloning and expression using recombinant techniques. These diagnoses may be used to determine whether T-cells are functional and the degree to which a T-cell population has been stimulated.
    Type: Grant
    Filed: December 15, 1987
    Date of Patent: February 19, 1991
    Assignee: The Board of Trustees of the Leland Stanford Jr. Univ.
    Inventors: Alan M. Krensky, Mark Davis, Thomas Schall, Jan Jongstra
  • Blood filtering metering device
    Patent number: 4987085
    Abstract: Constructions are provided for removing interfering red blood cells from a blood sample and providing a measured amount of serum or plasma to a pad. The pad serves as a bridge for the transfer of reagent between two bibulous strips, resulting in transfer of reagent solution through the pad and transport of a material to be measured to the measuring region of the strips. Particularly, glass fiber membranes are used in conjunction with cellulosic membranes to minimize red blood cell lysis, remove red blood cells and provide a measured amount of sample.
    Type: Grant
    Filed: March 16, 1989
    Date of Patent: January 22, 1991
    Assignee: Chemtrak Inc.
    Inventors: Michael P. Allen, Urs A. Ramel, Anthony J. DeLizza
  • Transmembrane integrator sequences
    Patent number: 4983521
    Abstract: Novel DNA constructions are provided, as well as their expression products, involving the use of transmembrane integrator sequences joined from one to two open reading frames and optionally a signal sequence, particularly at the N-terminus. The DNA constructs when used with membranal translation systems provide for translocation of the peptides into the membrane. Alternatively, a signal sequence may be introduced internal to an open reading frame, where the resulting translation product may be processed by a membrane to provide two peptides.
    Type: Grant
    Filed: September 12, 1986
    Date of Patent: January 8, 1991
    Assignee: The Regents of the University of California
    Inventors: Vishwanath R. Lingappa, Charles S. Yost
  • Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
    Patent number: 4978332
    Abstract: A pharmaceutical composition and method of treating cellular disorders involving abnormal solid cellular growths which comprises administering a pharmaceutical composition containing cytotoxic agents in combination with a vasoconstrictive drug. Enhanced effectiveness of the composition is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Agents may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.
    Type: Grant
    Filed: September 28, 1987
    Date of Patent: December 18, 1990
    Assignee: Matrix Pharmaceutical, Inc.
    Inventors: Edward E. Luck, Dennis M. Brown
  • Method of preparing derivatized polystyrene for spectroscopic studies
    Patent number: 4978724
    Abstract: Molded articles formed of polystyrene or other polymers containing an aromatic moiety can be derivatized on the surface of the article by subjecting the molded article to a chemical reaction wherein the reaction media utilizes tetramethylsulfone as the reactant solvent and a suitable substituent group which is substituted on to the aromatic moiety of the polystyrene or other polymer by electrophilic substitution. By choosing the substituent group to further include a leaving group, further substitution of the primary substituent can be effected normally by nucleophilic substitution reaction. In this way, biologically important molecules can be attached to a polystyrene or other aromatic containing polymer without effecting certain properties of the molded article such as its optical or spectroscopic clarity.
    Type: Grant
    Filed: December 30, 1986
    Date of Patent: December 18, 1990
    Assignee: Applied ImmuneSciences, Inc.
    Inventor: Brian R. Clark
  • Methods and compositions for expression of BTI endotoxin
    Patent number: 4978623
    Abstract: DNA sequences are provided coding for Bacillus thuringiensis var. israelensis (BTI) endotoxin, employing bacterial hosts which produce a protein having insecticidal activity for dipteran insects.The bacteriophage lambda strain SYN A4-1 was deposited at the A.T.C.C. on Feb. 22, 1984, and given Accession No. 40098.
    Type: Grant
    Filed: January 13, 1987
    Date of Patent: December 18, 1990
    Assignee: Snytro Corporation
    Inventors: Alan M. Walfield, Thomas J. Pollock
  • Therapeutically active compositions of pseudo-peptide of glutamyl-aspartic acid
    Patent number: 4975418
    Abstract: Therapeutically active pseudo-peptide characterized in that it comprises at least the sequence of the .gamma.-glutamyl-aspartic acid or one of its derivatives. Said pseudo-peptide may be used in the preparation of a pharmaceutical composition useful particularly in the treatment of epilepsy or affections of the central nervous system in general.
    Type: Grant
    Filed: January 11, 1988
    Date of Patent: December 4, 1990
    Assignee: Centre National de la Recherche Scientific (CNRS)
    Inventors: Arielle Ungerer, Jean De Barry, Yves L. J. Boulanger, Monique Schmitz-Bourgeois
  • Human serine protease gene
    Patent number: 4973555
    Abstract: Novel human serine proteases are provided characterized by expression in cytotoxic killer cells, being about 25.8kD, and having the amino acid residues of the serine protease charge-relay catalytic mechanism conserved. The proteases can be produced by recombinant DNA technology. The cDNA is also provided.
    Type: Grant
    Filed: December 31, 1986
    Date of Patent: November 27, 1990
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Howard K. Gershenfeld
  • Quantitative diagnostic assay employing signal producing agent bound to support and measuring migration distance of detectable signal
    Patent number: 4973549
    Abstract: Methods and kits are provided for detecting analytes, which can be measured directly or indirectly, by production of an enzymatic product. The enzymatic product reacts with a signal producing reagent bound to a bibulous strip. Various devices are employed for producing a reaction, directly or indirectly, with the analyte and then providing for migration of the product through the bibulous strip with reaction with the reagent to produce a detectable signal. The distance from a pre-determined site to the border of the detectable signal is a quantitative measure of the analyte in the sample.
    Type: Grant
    Filed: June 22, 1987
    Date of Patent: November 27, 1990
    Assignee: Chemtrak Corporation
    Inventors: Pyare Khanna, Prithipal Singh
  • Plasma processing device with anaphylatoxin remover
    Patent number: 4963265
    Abstract: Blood derived fluids are subjected to modification resulting in the production of anaphylatoxins. The anaphylatoxins may then be removed by passing the modified blood through silicic acid particles in an amount sufficient to substantially reduce the anaphylatoxins, while still retaining the other blood components and without affecting adversely the use of the blood for the patient.
    Type: Grant
    Filed: May 6, 1988
    Date of Patent: October 16, 1990
    Assignee: Applied ImmuneSciences, Inc.
    Inventors: Thomas B. Okarma, Brian R. Clark, L. Bernard Lerch, Chin-Hai Chang
  • Sample pad assay initiation device and method of making
    Patent number: 4959324
    Abstract: A self-contained assay device is provided, where an analyte may be detected or be quantitated by measuring the distance of a detectable signal from a predetermined site. The device employs two strips separated by a gap, where a flow path is completed by movement of a sample receiving pad into the gap. The movement of the sample receiving pad also results in release of a reagent solution which is then transported through the pad into the quantitation area where the amount of analyte may be determined. Various chemistries may be employed for providing a detectable signal.
    Type: Grant
    Filed: May 18, 1989
    Date of Patent: September 25, 1990
    Assignee: ChemTrak, Inc.
    Inventors: Urs A. Ramel, Michael P. Allen, Prithipal Singh
  • Cloning or expression vectors containing the avian erythroblastosis virus genome and cells transfected by these vectors
    Patent number: 4957865
    Abstract: The invention relates to a virus for cloning or expression of a foreign gene, characterized in that it consists of all or part of the genome of avian erythroblastosis virus and contains at least one foreign gene situated between the 3 LTR sequences.
    Type: Grant
    Filed: June 4, 1986
    Date of Patent: September 18, 1990
    Assignee: Institut National de la Recherche Agronomique (INRA)
    Inventors: Jacques Samarut, Gerard Verdier, Miloud Benchaibi, Pierre Savatier, Didier Poncet, Frederic Flamant, Jiao-Hao Xiao, Pierrick Thoraval, Frederique Chambonnet, Victor Nigon
  • Mammalian peptide expression in plant cells
    Patent number: 4956282
    Abstract: Novel constructs are provided for expression of physiologically active mammalian proteins in plant cells, either in culture or under cultivation. The constructs provide a promoter functional in a plant host, a structural gene coding for mammalian protein and a terminator functional in a plant host. The construct is introduced into a plant cell to become integrated into the plant genome for expression in the plant cells or plants. The plant cells may be harvested and the mammalian protein isolated in physiologically active form.
    Type: Grant
    Filed: July 29, 1985
    Date of Patent: September 11, 1990
    Assignee: Calgene, Inc.
    Inventors: Robert M. Goodman, Vic C. Knauf, Catherine M. Houck, Luca Comai
  • Covalent attachment of macromolecules on substrate surfaces
    Patent number: 4933410
    Abstract: Uncrosslinked polystyrene surfaces are derivatized under Friedel-Crafts conditions in a tetramethylenesulfone solvent using a substituted N-hydroymethyl acetamide derivatizing agent. The substitutent is subject to nucleophilic substitution to allow for the binding of a wide variety of molecules, particularly specific binding pair members, to the surface. Clarity is maintained for monitoring observation of events on the surface through the polystyrene.
    Type: Grant
    Filed: March 29, 1989
    Date of Patent: June 12, 1990
    Assignee: Applied Immunesciences, Inc.
    Inventor: David Okrongly
  • Production of substantially pure fructose
    Patent number: 4927757
    Abstract: A process is disclosed for the production of substantially pure fructose from sucrose-containing substrates. The process comprises converting the sucrose to levan and glucose, purifying the levan by membrane technology, hydrolyzing the levan to form fructose monomers, and recovering the fructose.
    Type: Grant
    Filed: July 29, 1988
    Date of Patent: May 22, 1990
    Assignee: Idaho Research Foundation, Inc.
    Inventors: Herbert J. Hatcher, John J. Gallian, Stephen A. Leeper
  • Treatments employing drug-containing matrices for introduction into cellular lesion areas
    Patent number: RE33375
    Abstract: Treatment of cellular disorders involving abnormal solid cellular growths involves introduction of cytotoxic reagents dispersed in a physiologically acceptable proteinaceous matrix into the solid cellular growth or area of an existing or removed solid cellular growth. Enhanced effectiveness of the drug is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Other drugs may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: October 9, 1990
    Assignee: Matrix Pharmaceuticals, Inc.
    Inventors: Edward E. Luck, Dennis M. Brown